Project Phases

Phase 0 – (3-4 weeks) 

• Antigen Design and Production: We offer full-spectrum services including the design, production, and conjugation of immunogens and antigens. Our focus on hybridoma technology ensures targeted screening processes that maximise the potential for successful outcomes. 

Phase 1 – (2-12 weeks) 

• Immunisation and Testing: We immunise four hosts, collect test bleeds, and typically assess immune responses through ELISA titres, ensuring robust data to guide the next steps. 

Phase 2 – (3 weeks) 

• Fusion and Screening: Fusion of immune cells with myeloma cells followed by screening to identify potentially valuable hybridomas. 

Phase 3 – (2-6 weeks) 

• Subcloning: Subcloning of selected hits of interest to ensure monoclonality and stability. 

Phase 4 – (4 weeks) 

• Hybridoma Preparation: This phase involves the preparation and scale-up of hybridomas, including secure cell banking for future use. 

Phase 5 – (4-6 weeks) 

• Scale-Up: We offer extensive scale-up options, including serum-free media and high-density culture techniques, ensuring scalability for large-scale antibody production. 

Phase 6 – (2 weeks) 

• Purification and Characterisation: Our final phase includes the purification, buffer exchange, and comprehensive characterisation of your monoclonal antibodies, ensuring they meet your exact specifications.